
    
      This open label, single-arm and multicenter phase II study is designed to evaluate Objective
      Response Rate (ORR) of first-line with anti-EGFR monoclonal antibody（SCT200）and standard
      chemotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
    
  